Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 7 | 2023 | 224 | 2.040 |
Why?
|
| Medical Oncology | 5 | 2023 | 35 | 1.530 |
Why?
|
| Mutation | 2 | 2019 | 325 | 1.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 222 | 0.910 |
Why?
|
| Patient Selection | 3 | 2022 | 170 | 0.910 |
Why?
|
| Oncologists | 1 | 2021 | 2 | 0.750 |
Why?
|
| Adolescent | 11 | 2023 | 2076 | 0.730 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2020 | 1 | 0.710 |
Why?
|
| Cyclosporine | 1 | 2020 | 13 | 0.700 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 124 | 0.650 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2019 | 1 | 0.640 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 2 | 0.640 |
Why?
|
| Influenza B virus | 1 | 2019 | 1 | 0.640 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2019 | 1 | 0.640 |
Why?
|
| Membrane Cofactor Protein | 1 | 2019 | 2 | 0.640 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 14 | 0.630 |
Why?
|
| Plasma Exchange | 1 | 2019 | 11 | 0.630 |
Why?
|
| Spectrin | 1 | 2018 | 1 | 0.630 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2018 | 1 | 0.630 |
Why?
|
| Genes, Recessive | 1 | 2018 | 2 | 0.630 |
Why?
|
| Influenza, Human | 1 | 2019 | 39 | 0.620 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 46 | 0.620 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 75 | 0.620 |
Why?
|
| MicroRNAs | 1 | 2019 | 52 | 0.610 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 84 | 0.600 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 74 | 0.590 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 98 | 0.590 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 102 | 0.590 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 3 | 0.550 |
Why?
|
| Orbital Neoplasms | 1 | 2016 | 7 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 351 | 0.540 |
Why?
|
| Child | 7 | 2023 | 1277 | 0.530 |
Why?
|
| Young Adult | 8 | 2023 | 1855 | 0.520 |
Why?
|
| Heavy Chain Disease | 1 | 2015 | 3 | 0.490 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 6 | 0.480 |
Why?
|
| Prognosis | 4 | 2020 | 739 | 0.460 |
Why?
|
| Humans | 18 | 2023 | 25692 | 0.460 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2014 | 5 | 0.450 |
Why?
|
| Osteosarcoma | 1 | 2013 | 27 | 0.420 |
Why?
|
| Membrane Proteins | 1 | 2014 | 151 | 0.420 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 209 | 0.390 |
Why?
|
| Bone Neoplasms | 1 | 2013 | 104 | 0.390 |
Why?
|
| Male | 8 | 2020 | 13917 | 0.310 |
Why?
|
| Quality of Life | 3 | 2023 | 600 | 0.230 |
Why?
|
| Communication | 2 | 2022 | 119 | 0.220 |
Why?
|
| Fertility Preservation | 1 | 2022 | 3 | 0.210 |
Why?
|
| Quality Improvement | 1 | 2022 | 132 | 0.190 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 221 | 0.180 |
Why?
|
| Child Health | 1 | 2020 | 3 | 0.170 |
Why?
|
| Administration, Oral | 1 | 2020 | 103 | 0.170 |
Why?
|
| Infant | 2 | 2018 | 529 | 0.170 |
Why?
|
| Oligoribonucleotides | 1 | 2019 | 1 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 24 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 16 | 0.160 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 847 | 0.160 |
Why?
|
| Female | 5 | 2020 | 14273 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2019 | 246 | 0.150 |
Why?
|
| Cell Proliferation | 1 | 2019 | 167 | 0.150 |
Why?
|
| Child, Preschool | 2 | 2018 | 640 | 0.150 |
Why?
|
| Apoptosis | 1 | 2019 | 177 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2019 | 139 | 0.140 |
Why?
|
| Mice | 2 | 2019 | 1345 | 0.140 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2017 | 29 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 410 | 0.140 |
Why?
|
| beta Catenin | 1 | 2017 | 59 | 0.130 |
Why?
|
| Age Factors | 1 | 2019 | 716 | 0.130 |
Why?
|
| Adult | 4 | 2022 | 7336 | 0.130 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2015 | 2 | 0.120 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2015 | 8 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 25 | 0.120 |
Why?
|
| Rituximab | 1 | 2015 | 45 | 0.120 |
Why?
|
| Animals | 2 | 2019 | 3510 | 0.110 |
Why?
|
| Metastasectomy | 1 | 2013 | 7 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 198 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1084 | 0.100 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3220 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 509 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3231 | 0.070 |
Why?
|
| Risk Factors | 1 | 2013 | 2224 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 2023 | 5 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 67 | 0.050 |
Why?
|
| Technology | 1 | 2021 | 5 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 143 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 227 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 17 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 14 | 0.040 |
Why?
|
| Heterografts | 1 | 2017 | 12 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2017 | 107 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 140 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 217 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 311 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 588 | 0.030 |
Why?
|
| United States | 1 | 2018 | 1943 | 0.020 |
Why?
|